Clinical Trial

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a single center, single arm, phase II, prospective study to evaluate the safety and effectiveness of HAIC combined with TAE plus an ICI and an TKI in adult patients (aged ≥18 years) with unresectable intrahepatic cholangiocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-25.
Status change: Recruiting → Active, Not Recruiting 2024-11-18
Trial Details
NCT Number NCT06239532
Lead Sponsor Qilu Hospital of Shandong University
Collaborators: BeiGene
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 28 participants
Start Date 2022-09-27
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-21